Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Glia. Author manuscript; available in PMC 2010 February 1.
Published in final edited form as:
PMCID: PMC2674560

Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Aβ42


Microglial phagocytosis contributes to the maintenance of brain homeostasis. Mechanisms involved however, remain unclear. Using Aβ42 solely as a stimulant, we provide novel insight into regulation of microglial phagocytosis by rafts. We demonstrate the existence of an Aβ42 threshold level of 250pg/ml, above which microglial phagocytic function is impaired. Low levels of Aβ42 facilitate fluorescent bead uptake, whereas phagocytosis is inhibited when Aβ42 accumulates. We also show that region-specific raft clustering occurs prior to microglial phagocytosis. Low Aβ42 levels stimulated this type of raft aggregation, but high Aβ42 levels inhibited it. Additionally, treatment with high Aβ42 concentrations caused a redistribution of the raft structural protein flotillin1 from low to higher density fractions along a sucrose gradient. This suggests a loss of raft structural integrity.

Certain non-steroidal anti-inflammatory drugs, e.g. the COX-2-specific NSAID, celecoxib, raise Aβ42 levels. We demonstrated that prolonged celecoxib exposure can disrupt rafts in a manner similar to that seen in an elevated Aβ42 environment: abnormal raft aggregation and Flot1 distribution. This resulted in aberrant receptor recruitment to rafts and impaired receptor-mediated phagocytosis by microglial cells. Specifically, recruitment of the scavenger receptor CD36 to rafts during active phagocytosis was affected. Thus, we propose that maintaining raft integrity is crucial to determining microglial phagocytic outcomes and disease progression.

Keywords: microglia, phagocytosis, rafts, CD36


Rafts are liquid ordered microdomains consisting of specific proteins, cholesterol and sphingolipids in a defined stoichiometry (Simons and Ehehalt 2002). In their native state, raft size can vary from 50–100 nm (Simons and Ikonen 1997), although recent reports have documented smaller raft sizes (5–50 nm) (Hancock 2006; Sharma et al. 2004). Raft structure is based on flotillin/reggie protein oligomers interspersed with lipids, like GM1 ganglioside (Langhorst et al. 2005). Flotillin1 (Flot1) is a raft structural protein and is considered to be a major indicator of raft structural integrity. Flot1, however, may also be involved in signaling processes and has been visualized in a number of different subcellular locations including the Golgi, endosomes and phagosomes (Babuke and Tikkanen 2007).

As discreet structural entities, rafts function as platforms for spatio-temporal orchestration of cellular signaling cascades including apoptosis, cytokine signaling, endocytic recycling, and phagocytosis (Fullekrug and Simons 2004; Simons and Ikonen 1997). These reports also show that in response to stimuli, rafts aggregate to form activated clusters through recruitment of other rafts and crosslinking with associated cell-surface molecules. It is this organizational capability that makes them vital to the regulation of cellular processes. Further, rafts have been implicated in the pathogenesis of many neurodegenerative diseases. For instance, processing of the amyloid precursor protein (APP) by β- and γ-secretases occurs within rafts (Ehehalt et al. 2003), with the resulting Aβ42 being neurotoxic (Korotzer et al. 1993). Thus, examining the role of rafts may provide some mechanistic insight into disease pathogenesis.

While raft activation plays a critical role in peripheral macrophage phagocytosis (Kay et al. 2006), this has yet to be demonstrated in the brain macrophage, the microglia. Here we examine whether rafts play a role in the regulation of microglial phagocytosis. Phagocytosis entails the recognition of material of interest, followed by molecular and morphological changes that enable tethering, signaling, engulfment and internalization of material through formation of a phagocytic cup (Gregory and Devitt 2004). Recognition mechanisms are initiated through specific cell surface recognition receptors, depending on the material being cleared. For instance, pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), use pathogen-associated molecular patterns (PAMPS) for clearing pathogens (Kaisho and Akira 2006). Morphological changes include assumption of an amoeboid shape, extension of pseudopodia for phagocytic cup formation, and phagosome closure with regulated actin rearrangement (Swanson et al. 1999). A defect in these mechanisms results in impaired phagocytosis (Paresce et al. 1996).

Phagocytosis is important for maintaining healthy cellular environments. Removal of debris can contribute to the modulation of immune responses by promoting survival and growth of surrounding cells (Reddy et al. 2002). Furthermore, reduced or defective clearance of debris or unwanted proteins can be associated with the initiation of autoimmune diseases such as type 1 diabetes and systemic lupus erythematosus, as well as upregulation of inflammatory processes during traumatic brain injury and neurodegeneration (Akiyama et al. 2000; Koshinaga et al. 2000; Krysko et al. 2006; O'Brien et al. 2002). Thus, disruption of the phagocytic process can severely impact the development of human disease through persistent inflammation and subsequent tissue damage (Krysko et al. 2006).

In the brain, defective clearance has been implicated in the development of proteinopathies and neurodegeneration (Bard et al. 2000). For instance, increased deposition of specific proteins in the brain with age, e.g. amyloid-β42 (Aβ42), may be a causative factor in both age-related neurodegeneration and Alzheimer’s Disease (AD) (Monaco et al. 2006; Selkoe 2001). Such deposition has been linked to increased microglia activation in aging mouse brain and age-related neurodegeneration that manifests as increased production of interleukin (IL)-1 and IL-6, astrocyte activation, APP and apolipoprotein E (APOE) transcription, and Aβ42 production. In addition, anti-inflammatory, protective factors such as transforming growth factor-β1 (TGF-β1) and insulin-like growth factor 1 (IGF-1) decline with age-related neurodegeneration (Griffin 2006; Griffin et al. 2006; Puglielli 2007; Sierra et al. 2007). Despite the increased activation, microglial phagocytic function, however, decreases with aging and in neurodegenerative diseases (Streit 2006).

Defective clearance of Aβ42 in the brains of Alzheimer’s disease (AD) patients has been associated with decreased microglial, and possibly infiltrating macrophage, function in clearing the excess protein (Fiala et al. 2005). A similar phenomenon exists in the inability of activated microglia to clear Aβ42 deposits in brains of mouse models of AD (Wyss-Coray et al. 2001). Areas of Aβ42 deposition have also been linked to an increased activation of microglia, inflammation, and altered enzyme activities including cyclooxygenase 2 (COX-2) (O'Banion et al. 1997; Rogers et al. 2002). Given that peripheral macrophages and microglia share a monocytic lineage, as well as phenotypic and functional characteristics (Chan et al. 2007), we propose that phagocytic activity in microglia will employ raft activation similar to that seen in peripheral macrophages.

There are numerous reports of the involvement of cell-surface receptors in the clearance of Aβ42 (Chung et al. 1999; Mitrasinovic and Murphy 2002; Paresce et al. 1996; Tahara et al. 2006; Wang et al. 2006b), including special types of receptors called scavenger receptors (SRs), such as SRA and SRB family members (Paresce et al. 1996), which may be present within rafts (Thorne et al. 2006; Triantafilou et al. 2006). However, a current model suggests an unconventional mechanism for microglial phagocytosis of fibrillar Aβ42 that uses a complex of CD36, a member of the SRB family, α6β1 integrin complex at the cell surface, and the integrin-associated adhesion receptor, CD47. This mechanism is does not involve the traditional FcRγI or FcRγIII (type I phagocytosis) or complement receptors (type II phagocytosis) (Bamberger et al. 2003; Koenigsknecht and Landreth 2004). CD36 is a raft-resident, cell surface glycoprotein with expression limited to specific cellular subtypes including monocytes and macrophages (Thorne et al. 2000). CD36 is expressed in microglia, increases in AD (Coraci et al. 2002; Ricciarelli et al. 2004), and has been linked to microglial activation, migration and phagocytosis (Bottcher et al. 2006; El Khoury et al. 2003; Eto et al. 2003; Moore et al. 2002; Ren et al. 1995; Stuart et al. 2007). Thus, CD36 serves as a good candidate for investigating raft recruitment of receptors during phagocytosis.

The presence of an increased inflammatory component in aging and AD, in addition to the fact that rheumatoid arthritis patients generally did not develop AD, spurred the use of non steroidal anti-inflammatory drugs (NSAIDs) in clinical trials. These trials, however, have not yielded much success for reasons that may relate to type of NSAID used. Since recent studies reported that some COX-2-selective NSAIDs increased levels of Aβ42 in vivo and in vitro, shifting the Aβ42/Aβ40 ratio in the direction that facilitates deposition; we used celecoxib as a pharmacological inducer of Aβ42(Kukar et al. 2005; Leuchtenberger et al. 2006) and compared the effects to direct treatment with Aβ42 on microglial phagocytosis, raft aggregation and receptor recruitment. We demonstrate that microglial raft clustering directly reflects phagocytic function, and that raft recruitment of specific receptors, such as CD36, is necessary for microglial phagocytosis.

Materials and Methods


42 (American Peptide, Sunnyvale Ca) was resuspended in sterile water at 0.5 mg/ml and fibrillized by incubation at 37°C for 5 days. Fresh dilutions of 100 pg/ml, 250 pg/ml, 500 pg/ml and 500 ng/ml were made in media [DMEM/5% horse serum/5% FBS/1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). Celecoxib, γ-secretase inhibitor MDL 28170, zymosan and filipin were obtained from Sigma-Aldrich (St. Louis, MO). Celecoxib stock: at 0.1M/DMSO. 20 µM working solution was made in media. Quality control and stability assays were performed by Research Triangle Institute (RTP, NC). For all treatment endpoints, untreated controls were compared to 0.02% DMSO vehicle controls and no significant differences were found (data not shown).

Microglia cultures

Primary mixed glia cultures were prepared from CD1 mice or Long Evans hooded rats (Charles River Laboratories, Raleigh, NC) as previously described (McCarthy and de Vellis 1980) with slight modification. Cortices were removed from 10 PND 2 pups, freed of meninges, and placed in saline 1 buffer (140 mM NaCl, 5.36 mM KCl, 1.01 mM Na2HPO4, 8.6 mM KH2PO4, 22 mM glucose, 0.002g/L phenol red) on ice. Tissue was minced and digested (1% trypsin) prior to sequential filtration through 165 and 42 µm nylon mesh. The filtrate was incubated at 37°C for 15 min in a T175 flask (BD Biosciences-Falcon, Franklin Lakes, NJ) then cultured in media, at 6–7 × 104 cells/cm2 at 37°C with 5% CO2/ambient O2 until confluence was reached. The overlaying microglia were shaken off at 35 rpm at 37°C (mouse: 6 hrs, rat: 7 hrs) and plated (7000–7500 cells/cm2) onto 12mm sterile, poly-D-lysine treated glass coverslips (BD Biosciences), placed in multi-well plates (Falcon), or into fresh T75 flasks (Falcon) and incubated for further treatment. All experiments were conducted according to an animal use protocol approved by NIEHS/NIH Animal Care and Use Committee.

Identification of raft clustering

Mouse microglia were grown on coverslips overnight then treated with normal media or media containing Aβ42 (250 pg/ml, 500 pg/ml, or 500 ng/ml) for 3, 6 and 24 hrs. Cells were washed and raft clustering was assessed by GM1 ganglioside distribution using the Lipid Raft Vybrant Assay kit (Promega, Madison WI). Following fixation in 4% paraformaldehyde/PBS for 15 min at 4°C, cells were stained with FITC-labeled Griffonia simplicifolia IB4-lectin (1:200; Sigma-Aldrich) in 1X Automation buffer (Fisher Scientific, Pittsburgh, PA) plus 1mM Mg2+ and Ca2+, and mounted with Prolong Gold Anti-Fade (Invitrogen). Positive controls were treated with 100 pg/ml Aβ42 for 3 hrs or 0.5 mg/ml zymosan for 1 hr. For each treatment, cells from 5 random fields (20× mag) were imaged from duplicate wells and the average % of cells with phagocytic cup formations determined by morphological analysis. The area and perimeter of GM1 clusters in the phagocytic cup region and those outside of the cup region was determined using Metamorph™ software v6.0 (AutoQuant Imaging, Inc. Bethesda, MD). To disrupt rafts, cells were incubated with 0.02 mg/ml filipin at 37°C for 1 hr. Cell viability was also measured using Promega Cell Titer Glo Kit protocol.


Images were acquired with a Nikon Eclipse TE-2000E microscope (Melville, NY) and processed using Metamorph™ software. 0.2 µm Z stack images were taken at 60× and subjected to point spread function-based iterative 3-D blind deconvolution. For fluorescent quantification of raft aggregation, individual z-plane images were thresholded and regions of GM1 aggregation were expressed as number of thresholded pixels/µm2. The area and perimeter of raft regions and co-localization of fluorophore overlap were measured.

Isolation of DRMs

Microglia cultures were pooled to obtain 10 × 106 cells, centrifuged at 10,000×g for 1 min, the supernatant removed, the pellet frozen on dry ice, and stored at −80°C. Cell pellets were thawed on ice, resuspended in 225 µl of lysis buffer [1× tris buffered saline (TBS; pH 8), 1% Triton-x 100, 1% proteinase inhibitor cocktail, 1mM PMSF, 5mM NaF, 1mM Na Orthovanadate (Sigma-Aldrich)] in SW60 ultracentrifuge tubes, and incubated on ice for 30 min. While on ice, the suspension was mixed with 225 µl of 85% sucrose/TBS. 3.0 mls of 35% sucrose/TBS was overlaid, followed by 675 µl 5% sucrose/TBS. The tubes were centrifuged at 38,500 rpm (200,000×g) for 18 hrs at 4°C. Fifteen fractions of 260 µl each were gently removed from the top of the tube and individually aliquoted. The fractions were stored at −80°C.

Western blot analyses

DRM fractions were thawed on ice and protein concentrations measured (BCA Assay, Pierce, Rockforld, IL). Equal sample volumes (15 µl) (Arvanitis et al. 2005), were loaded onto 4–12% SDS polyacrylamide gels. High density fractions (fractions 13–15) were pooled. Protein was transferred onto PVDF membranes (Invitrogen). Membranes were incubated with an antibody to flotillin 1 (1:1000, Flot1, cat# 610821, BD Biosciences). Invitrogen Western Breeze Chemiluminescent kits were used for protein detection. Blots were processed using the Kodak Digital Imaging system. Membranes were stripped and re-probed with an antibody to transferrin receptor (1:500, TfR; cat# 13-6800, Zymed, San Fransisco, Ca). TfR, which is not associated with rafts, was used as a non- raft marker.

Phagocytic bead uptake

Mouse microglia were treated with either vehicle or a single dose of 100, 250, 500 pg/ml, or 500 ng/ml Aβ42 and incubated for 0, 3, 6, 21, 24, or 27 hrs. For multiple dosing experiments, cells were dosed at 0, 6, 18, and 24 hrs with 250 pg/ml, 500 pg/ml, or 500 ng/ml of Aβ42, and incubated for 0, 3, 6, 2, 24, or 27 hrs. Cell media was changed at each addition. Cells were washed and fixed in 4% paraformaldehyde/4% sucrose/PBS for 20 min at 4°C, washed and stained with FITC-labeled IB4-lectin as previously described. For the 0 hr time point, the beads were added and immediately removed. As a positive control for induced phagocytosis, cells were exposed to 0.5 mg/ml zymosan/media with heat-inactivated serum for 1 hr. Phagocytic activity was determined by the uptake of beads [1ul/ml media of 1um Texas Red-labeled fluorescent tracker beads (Invitrogen)] over different time periods. For each time point, the number of bead-positive cells from 6 random fields/well was determined from duplicate wells. Data represents the total number of bead-positive cells as a percent of matched controls.

42 ELISA and γ-secretase activity

Mouse microglia were plated as described and treated with DMSO vehicle or 20 µM celecoxib for 0, 6, 12, or 24 hrs. From each well, 100 µl of media was collected. Plated cells were harvested by scraping to determine released and intracellular Aβ42 levels using an Aβ42-specific ELISA (IBL, Japan, #27711, cross-reacts with mouse protein, discontinued). To determine γ-secretase activity, plated microglia were pre-treated with 200 µM MDL 28170 for 1 hr at 37°C, washed and treated with media or 20 µM celecoxib for 0, 6, 12, or 24 hrs. The media was analyzed by ELISA for Aβ42 release and the cells harvested and assayed for γ-secretase activity (R&D Systems) at OD450.

Quantitative Real Time PCR

Mouse microglia were plated into 24 well dishes as described above and RNA was isolated using the Qiagen RNeasy kit (Valencia, Ca). 1 µg of total RNA was used to prepare cDNA according to the Superscript II RNase Resverse Transcriptase manufacturer’s protocol (Invitrogen). qRTPCR for IL-1β, IL-1α, IL-6, TGFβ1, IGF-1, and GAPDH were conducted using the ABI prism 7700 system™ Sybrgreen protocol (Applied Biosystems, Foster City, Ca). Primer sequences are listed in table 1.

Table 1
qRTPCR Primer Sequences

CD36 and CD47 localization in microglia rafts

Cells were stained for rafts as above, fixed, placed in blocking solution (2%BSA/10% horse serum/PBS) for 1 hr at 25°C, followed by incubation with anti-mouse CD36 (cat# 100011, Cayman Chemical, Ann Arbor MI; 1:200) or anti-mouse CD47 (cat# AF1866, R&D systems, Minneapolis, MN; 1:100) for 1 hr. Cells were washed and incubated with an Alexafluor 350 secondary antibody (1:1000, Molecular Probes-Invitrogen) and IB4 for 1 hr at 25°C and mounted. Cells were chosen randomly from 5 fields and the average co-localization between GM1 and CD36 or CD47 calculated. Data is representative of 3 independent experiments done in duplicate. Exposure time was constant. Controls included absence of primary antibodies or with IgG alone. Western blot confirmed specificity of the anti-CD36 antibody (88 kDa).

Statistical Analyses

Data analysis was conducted with GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego California USA, using a Chi Square for categorical data, a Mann Whitney U-test for comparison of non-parametric data, a one-way ANOVA followed by a Dunnett’s t-test for comparisons back to control or 0 time point, and two-way ANOVA with treatment, time, and replicates as main factors followed by a Bonferroni post-hoc test for independent group means comparisons.


Effects of different Aβ42 concentrations on microglial phagocytosis

Phagocytic stimulation was confirmed by bead uptake over a 27 hr period, in microglia treated with a low concentration (100 pg/ml) of fibrillized Aβ42 (Fig. 1a). We examined phagocytosis over this time period to investigate cumulative effects of Aβ42 on microglial phagocytosis. As a positive control for phagocytosis, we measured bead uptake induced by treatment with 0.5mg/ml zymosan in DMEM containing heat-inactivated serum. Zymosan can activate the complement pathway and stimulate inflammatory responses (Keystone et al. 1977) that include active phagocytosis and phagocytic cup formation (Tohyama and Yamamura 2006). Heat-inactivated serum was used instead of normal serum to prevent responses that could be due to complement factors present in serum. All changes observed in bead uptake were confirmed in cells maintained in macrophage defined serum-free media.

Fig. 1
A high Aβ42 environment inhibits phagocytosis in microglia

Next, we investigated the effects of higher concentrations of Aβ42. Cells received an acute dose of 250 pg/ml, 500 pg/ml, or 500 ng/ml fibrillar Aβ42 at the 0 hr time point. Treatment with Aβ42 at these levels generally inhibited microglial bead uptake as compared to controls, at all time points tested through 27 hrs; however, a slow, steady recovery was evident at 21, 24 and 27 hrs (Fig. 1b). To account for possible protein degradation of Aβ42 within the media, which could relieve the inhibitory effect on microglial phagocytosis during this late stage recovery phase, a multiple dosing regimen was used. Cells were initially dosed at 0 hrs and then again at 6, 18, and 24 hrs with 250 pg/ml, 500 pg/ml, or 500 ng/ml of fibrillar Aβ42 to produce a state of continually high Aβ42 levels in the media. This dosing regimen for Aβ42 maintained a steady inhibition of microglial bead uptake throughout the experimental time course (Fig. 1c).

Rodent microglia contain membrane rafts

Membrane rafts are very small entities that can only be visualized with light microscopy following their clustering at the cell surface (Langhorst et al. 2005). Raft clustering was visualized in primary mouse microglia cultures with an antibody to Flot1 or with the Promega Lipid Raft vibrant assay, which uses fluorescently-tagged Cholera Toxin B (CT-B) to identify aggregation of the raft lipid, GM1 ganglioside. In FITC-labeled Griffonia simplicifolia IB4-lectin positive microglia, Flot1 was present in a punctate distribution with minimal visibility at the cell surface (Fig. 2a). This pattern is consistent with previous work done in neurons (Persaud-Sawin et al. 2004) and other cells (Janich and Corbeil 2007), where Flot1 was not only present at the cell surface but within the cell body itself. Under normal culture conditions, some clustering occurs as cells respond to their immediate environment and surrounding cells. The average cluster size was 0.284 µm2 in area and 1.36 µm in perimeter (Suppl. Table 1). The average number of clusters within an individual cell was 7.25. The variance in each of these measures was within a 10–15% range.

Fig. 2
Membrane rafts are present in rodent microglia

To corroborate raft presence in primary microglia, cell lysates were subjected to 1% Triton-X 100 detergent isolation at 4°C, followed by sucrose gradient density ultracentrifugation (Brown and London 2000). This method allows for the separation of detergent-resistant membranes (DRM) fractions that are cholesterol- and sphingolipid-rich and have associated glycosylphosphatidylinositol-linked or acylated proteins that broadly define membrane rafts (Brown and Rose 1992; Lingwood and Simons 2007). A discontinuous sucrose density gradient of 5%/35%/85% was used to isolate rafts (Wang et al. 2006a). The requirement of approximately 10–15 × 106 cells per isolation necessitated the use of rat microglia. The total protein concentration in each fraction was consistently less in the upper, low density fractions 1–3 (0.05–.2 µg/ml) than in the middle (4–7) to high density fractions (8–15; 0.8–0.9 µg/ml). Since protein concentration did not provide a true baseline parameter for comparison across fractions, equal volume loading for the Western blot was used as previously described (Arvanitis et al. 2005). This method of loading accounts for the differential solubility of proteins in Triton-X 100 and the fact that proteins will be concentrated in specific fractions following sucrose density ultracentrifugation. DRM fractions were identified with an antibody to Flot1 and non-raft fractions were identified with an antibody to TfR by Western blot (Fig. 2a). Flot1 was consistently present in the low to medium density fractions only (1–5), consistent with published work (Macdonald and Pike 2005). TfR was absent from the first three fractions isolated from lysates by sucrose gradient. Hence, the first three fractions in our study are designated as the raft fractions.

Effects of different Aβ42 concentrations on microglial raft aggregation

To determine whether rafts were involved in the phagocytic process, we investigated whether raft clustering occurred following stimulation with 100 pg/ml Aβ42. As this is the first report quantifying raft aggregation, we define raft aggregation as the presence of concentrated accumulations of GM1 in a region-specific manner, e.g. possible clustering within the phagocytic cup formation. Since rafts increase in size as they cluster, the area and perimeter of GM1 clusters in the phagocytic cup area were quantified and compared to those occurring in the rest of the cell. We tested this following 3 hrs of 100 pg/ml Aβ42 or 1 hr with 0.5 mg/ml zymosan treatment; times during which phagocytosis is activated by low Aβ42 or zymosan, respectively. Both treatments induced phagocytic cup formation (% of cells with phagocytic cups: 79.5 with Aβ42; 89.5 with zymosan) with raft recruitment and clustering (Fig. 2, Table 1). Each dosing regimen created two different raft populations, one with larger clusters inside the cup region and the other with significantly smaller clusters outside of the cup region (P<0.001) (Suppl. Table 1).

We then examined the effect of higher Aβ42 concentrations on raft clustering and phagocytic cup formation following 6 hrs of treatment. We chose the 6 hr time point since this was the time at which maximum phagocytic inhibition occurred. Phagocytic cup formation was observed in 3% or less of the cells. High concentrations of Aβ42 stimulated raft aggregation; however, GM1 clusters were relegated to areas that lacked a phagocytic cup formation (Fig. 2, Suppl. Table 1). These clusters were mainly present at the leading edge or uropod of the cell, indicating the initiation of directional movement (Fig. 6a) (Seveau et al. 2001). Our results suggest that a high Aβ42 environment impairs both phagocytic cup formation and associated raft clustering. Next, we tested whether Aβ42 affects raft integrity as assessed by Flot1 and TfR protein distributions in DRMs. At an Aβ42 concentration of 100 pg/ml (Fig. 2c), Flot1 was normally distributed in the low density fractions. At higher concentrations (250 pg/ml) of Aβ42, Flot1 distribution not only shifted by one fraction into the higher density fractions, but there was also less of it, as indicated by the decreased band intensity, compared to treatment with 100 pg/ml Aβ42. This indicates some disruption of raft integrity.

Fig. 6
Celecoxib disrupts microglial raft structural integrity

Disrupting rafts inhibits raft aggregation and phagocytosis

If rafts are required for phagocytosis, then their disruption should inhibit raft clustering and phagocytosis. Cells were pre-treated with 0.02 mg/ml of the cholesterol sequestering agent, filipin, allowing raft disruption without decreased cell viability and raft clustering compared to untreated controls (Fig. 3a & b). Following filipin treatment, the sizes of GM1 aggregates were, on average, 0.195 µm2 in area with a 1.31 µm perimeter (Suppl. Table 1). Filipin pre-treatment prevented phagocytic cup formation. Filipin also inhibited bead uptake and Aβ42 production (Fig. 3c; Suppl. Table 2), suggesting that maintaining intact raft structures is necessary for phagocytosis. We next examined the effect of filipin on Flot1 distribution in DRMs. In control microglia, Flot1 was distributed in the low density raft fractions 1–3. Filipin treatment induced loss of Flot1 in fractions 1 and 2, and a shifted distribution to fraction 3 and the higher density fractions, 4–7. Flot1 band intensity was also lower than controls, suggesting decreased protein consistent with disruption of raft integrity (Fig. 3d). TfR protein distribution shifted in the opposite direction, where it was now present in the low density raft fractions 2 and 3. This also supports a decrease in the stability of the raft structure.

Fig. 3
Filipin disrupts microglial raft structural integrity

Celecoxib increases Aβ42in primary mouse microglia cultures

As celecoxib was shown to increase levels of Aβ42 in vivo and in vitro, we used it as a pharmacological inducer of Aβ42 (Kukar et al. 2005; Leuchtenberger et al. 2006). The effect of different concentrations of celecoxib (5, 10, 20 and 50 µM) on cell viability and the production of Aβ42 from primary mouse microglia was tested in vitro by cell proliferation assays and Aβ42-specific ELISA. 20 µM celecoxib treatment provided a consistent increase in Aβ42 (~600 pg/ml) with no effect on cell viability through 24 hrs (Fig. 4a). Compared to untreated and vehicle controls, celecoxib treatment significantly increased Aβ42 release at 3, 6, 12 and 24 hrs (Fig. 4b). We tested a time point at 1 hr and found no significant increase in Aβ42 levels over control (data not shown).

Fig. 4
Celecoxib increases Aβ42 levels in microglia

Microglia cells treated with celecoxib showed higher γ-secretase activity at 6 and 12 hrs, compared to untreated controls (Fig. 4c). Pre-treatment with the γ-secretase inhibitor, MDL 28170 (200 µM) followed by ccelecoxib, resulted in significantly lower Aβ42 levels, confirming that celecoxib treatment affects γ-secretase activity. We then measured intracellular levels of Aβ42 in cells treated with celecoxib. A cyclical increase in intracellular Aβ42 at 0 and 12 hrs of celecoxib treatment was observed (Fig. 4d). The very early increase in intracellular Aβ42 supports a rapid increase in γ-secretase activity with celecoxib treatment.

Effects of celecoxib on microglial phagocytosis

Cells were treated with 20 µM celecoxib for 0 – 27 hrs, producing an elevated level of Aβ42 in the media and phagocytosis was assessed via uptake of 1 µm Texas Red-labeled beads. For each time point, bead uptake after 20 µM celecoxib treatment was normalized to vehicle controls, accounting for any stimulation due to beads alone. We found no significant differences between untreated and vehicle-treated cells (data not shown). The period for examination was chosen to incorporate times at which Aβ42 was produced in culture (3 – 24 hrs) and to allow phagocytosis to occur (Swanson et al. 1999). Maximum bead uptake occurred at 3 hrs after treatment (Fig. 5). Between 6 – 21 hrs of treatment with celecoxib, no significant difference in bead uptake was detected in the treated cells as compared to the controls. However, with additional time, between 24 and 27 hrs, a significant reduction in bead uptake was observed in celecoxib-treated cells. This decrease in bead uptake occurred in the absence of any changes in cell viability or proliferation (data not shown).

Fig. 5
Celecoxib treatment inhibits phagocytosis in microglia

Prolonged treatment with celecoxib inhibits raft aggregation and microglial phagocytosis

We determined whether celecoxib treatment stimulated phagocytic cup formation and regional raft aggregation. Treatment with celecoxib for 3 hrs induced phagocytic cup formation in 60% ± 3.4 (SD) of the entire cultured cell population. Concomitant raft clustering occurred in two separate pools, one in the region of cup formation and the other outside of this defined region (Fig. 6a). The average area of GM1 clusters outside of the cup region was 0.17 µm2 with a 1.18 µm perimeter. Within the cup area, the size of GM1 clusters was significantly increased (P<0.0001), with an average area of 1.75 µm2 and perimeter of 5.97 µm (Suppl. Table 1) demonstrating raft recruitment. The percent distribution of GM1 clusters in the phagocytic cup also increased significantly (P<0.001) as compared to outside of the cup region, suggesting that raft recruitment to this area is a prerequisite for phagocytosis.

At 6 and 24 hrs after celecoxib treatment, raft aggregation significantly decreased with ≤ 3% of cells showing evidence of phagocytic cup formation, as compared to the 3 hr time point (P<0.001). In addition, raft clusters were, on average, smaller (0.3%0.6 µm2), fewer in number (P<0.0001) and present along the leading edge of the cell (Fig. 6a), similar to that seen with higher Aβ42. In cells displaying a phagocytic cup, there were no visible GM1 clusters within the cup, suggesting a lack of raft recruitment there at 6 – 24 hrs. These results were consistent with the inhibition of bead uptake by celecoxib at time points greater than 3 hrs. We demonstrated that celecoxib interferes with GM1 localization. Filipin inhibited the organized raft clustering that celecoxib induces (Fig. 6a). The pattern observed was similar to the effect of filipin alone.

Celecoxib affects raft integrity

As a measure of raft integrity, we investigated the effect of celecoxib on Flot1 distribution in raft fractions by Western blot (Fig. 6b). At 0 hrs treatment with 20 µM celecoxib, Flot1 was present in the low density raft fractions, 1–3, representing a normal distribution pattern. At 3 hrs after treatment, Flot1 was still present in low density fractions 2 and 3, but absent from fraction 1; similar to 100 pg/ml Aβ42 treatment. At 6 hrs, further redistribution of Flot1 to higher density fractions was observed. Interestingly, at this time point, there was a shift in Flot1 distribution out of raft fractions 1 and 2. Although still present in raft fraction 3, Flot1 could now be detected in higher density fractions 4–7. At 12 (not shown) and 24 hrs, the redistribution of Flot1 to the higher density fractions became more evident. A progressive transition of TfR to the lower density fractions 2 and 3, at 6 through 24 hrs was observed.

Celecoxib increases IL-1α and IL-6, but not TNFα

Microglia were treated with 20 µM celecoxib for 0, 6, 12, 24 and 48 hrs and mRNA levels of the tumor necrosis factor-α (TNFα), interleukin (IL)-1α, IL-1β, transforming growth factor-β1 (TGFβ1) and insulin-like growth factor 1 (IGF-1) were measured. Basal TNFα mRNA levels were just within the detectable range and no increase occurred with celecoxib treatment (relative fold change fell within the range of 0.5<fold induction over vehicle control<0.8; P>0.05 using ANOVA followed by the Dunnett’s t-test), corroborating previously reported results that celecoxib does not increase TNFα expression (Cuzzocrea et al. 2002). IL-6 mRNA levels in treated cells progressively increased over controls through 48 hrs of treatment (Fig. 7). A significant increase was seen in IL-1α, but not IL-1β mRNA levels, following 24 hrs exposure. mRNA levels of the anti-inflammatory cytokines, TGF-β1 and IGF-1, decreased.

Fig. 7
Celecoxib stimulates pro-inflammatory cytokine mRNA expression in mouse microglia

Raft localization of CD36 is disturbed by high Aβ42

We confirmed results by Landreth and colleagues (Bamberger et al. 2003) showing that clearance of Aβ42 by microglia involves the SRB member, CD36. We investigated whether prolonged celecoxib treatment would affect CD36 localization within microglia membrane rafts. In untreated cells, CD36 co-localized with GM1 ganglioside in rafts, with a 42.37 ± 2.3% degree of co-localization (Fig. 8a). In cells treated with 20 µM celecoxib for 3 hrs there was a significant increase in CD36 within rafts where the percent co-localization with GM1 was 66.35 ± 4.0% (P<0.05). This suggests recruitment into rafts in the region of the phagocytic cup (Fig. 8b). The presence of CD36 in some, but not all, rafts points to at least two discreet raft pools. At 6 hrs of celecoxib treatment, a time coinciding with decreased phagocytic activity, CD36 co-localization with GM1 decreased to 16.98 ± 0.01% (P<0.05), indicating its redistribution out of rafts (Fig. 8c). Where present, rafts and CD36 were no longer visible in the phagocytic cup.

Fig. 8
Celecoxib affects raft distribution of CD36 in mouse microglia

To ascertain whether receptor recruitment to rafts is specific, we examined CD47 since it was speculated that it may be involved in Aβ42 clearance (Bamberger et al. 2003). Microglia were treated with celecoxib for 3 and 6 hrs prior to measuring the degree of co-localization of CD47 to rafts (Fig. 9). In untreated cells, CD47 co-localization with rafts was 32 ± 2%. Treatment with celecoxib for 3 hrs induced movement of CD47 out of rafts, decreasing the amount of co-localization to 4 ± 0.07% (P<0.01). At 6 hrs, CD47 presence in rafts significantly increased to 14.5 ± 1.2%, as compared to the 3 hr time point (P<0.05), suggesting some re-entry. Together these data suggest that CD47 may not be involved in microglial phagocytosis of Aβ42, or it may serve as a negative regulator of phagocytosis.

Fig. 9
CD47 presence in rafts is not required for microglial phagocytosis


Increasingly, membrane rafts are being recognized as important components required for different vital cellular processes, including peripheral macrophage phagocytosis (Bottcher et al. 2006). Their importance as a potential pivot point in microglial phagocytic function, however, has not been previously investigated. As a novel approach to understanding mechanisms involved in the clearance of Aβ42, we investigated the importance of membrane rafts in regulating microglial phagocytosis. By examining raft aggregation through cell morphology and GM1 staining during phagocytic stimulation with direct Aβ42 addition or pharmacological treatment, we identified two inter-dependent processes that are required for efficient phagocytosis by microglia: (1) phagocytic cup formation and (2) localized raft aggregation in the phagocytic cup region. Moreover, raft aggregation occurred in two distinct pools, suggesting that the raft population is heterogeneous, with different pools varying in their respective lipid and/or protein components.

Existence of an Aβ42 threshold

In this study we investigated microglial responses to Aβ42, the most pathogenic form of Aβ. Whether rafts play a similar role in the phagocytosis of Aβ40 is not yet known. We demonstrate the existence of an Aβ42 threshold level of 250 pg/ml, above which microglial phagocytosis of fibrillar Aβ42 is severely inhibited. This value is comparable to the Aβ42 burden levels observed in the cerebrospinal fluid of patients suffering from early to mid-stage AD (500 nM) (Liu et al. 2005). One explanation for this may be that, at or above 250 pg/ml of fibrillar Aβ42, microglial receptors may become saturated with the peptide, rendering them incapable of efficient phagocytosis. An alternative may be that the increase in Aβ42 leads to cholesterol depletion, raft instability and subsequent cell death by autophagy (Cheng et al. 2006; Nixon 2007). With respect to the latter, we identified a shift in the Flot1 distribution into non-raft fractions following incubation with high Aβ42 concentrations, while TfR moved into raft fractions. This shift was also observed following treatment with filipin, which disrupts rafts through cholesterol sequestration. Our results demonstrate, for the first time, that levels of fibrillar Aβ42 above 250 pg/ml can produce definite disturbances in raft homeostasis and structural integrity that can lead to dysregulated microglia functions, including phagocytosis. Although a shift in Flot1 of one fraction was observed with our 100 pg/ml Aβ42 treatment, there was no loss of microglial phagocytic function. Various studies on raft isolation demonstrate that DRM fractions are generally seen from fractions 1 through 5, depending on isolation procedure and cell or tissue type (Brown and London 2000; Macdonald and Pike 2005; Wang et al. 2006a), suggesting that a shift to fraction 2 may not be detrimental to cellular function. This is supported by the observation that phagocytosis is not inhibited with 100 pg/ml Aβ42. Further shifts into fractions 3 and above, as seen at higher Aβ42 concentrations (250 pg/ml), however, do affect phagocytic function.

Celecoxib interferes with raft integrity and microglial phagocytosis

We confirmed a previous report that celecoxib raises Aβ42 levels (Kukar et al. 2005), in a cyclical manner. Maxfield and colleagues suggested the possibility that microglia may become so overloaded with Aβ42 in AD that they are rendered unable to efficiently degrade the protein (Chung et al. 1999). The observed cycling suggests that, in our system, Aβ42 does not accumulate intracellularly but may be degraded internally or secreted, over the time period tested. The lack of internal accumulation of fluorescent Aβ42 in microglia supported this (data not shown). This prompted us to examine possible effects of celecoxib on rafts. One study demonstrated that, at clinically relevant dose levels, celecoxib had no effect on membrane fluidity or activity of raft resident proteins such as alkaline phosphatase (Nair et al., 2006). Behl and colleagues (Gamerdinger et al. 2007), however, provide evidence that selective COX-2 inhibitors cause cholesterol-like decreases in membrane fluidity and increased association of APP and the β-secretase, BACE 1 in rafts, leading to substantial generation of Aβ peptide. Celecoxib can also affect sarco-endoplasmic calcium ATPases, similar to cholesterol (Johnson et al. 2002). Celecoxib may, therefore, exert raft-altering properties and, since raft integrity is cholesterol-dependent (Pike 2004), APP processing could also be affected (Simons et al. 1998). Our results support the Behl study (Gamerdinger et al. 2007) and demonstrate that celecoxib increased Aβ42 production via rafts, as filipin treatment prevented celecoxib-induced Aβ42. Further, since amyloidogenic processing via γ-secretase occurs within rafts (Ehehalt et al. 2003; Urano et al. 2005), and celecoxib increases γ-secretase activity (Kukar et al. 2005; Leuchtenberger et al. 2006), disrupting rafts will prevent celecoxib-induced Aβ42. Although celecoxib increased γ-secretase activity, this declined after 12 hrs of treatment. The leveling off of secreted Aβ42 shown in figure 1 supports this.

Additionally, celecoxib treatment appeared to structurally disrupt rafts, in a manner similar to a high Aβ42 environment; shifting Flot1 distribution toward the non-raft fractions. The trend observed with 3 and 6 hr celecoxib treatment was similar to 100 and 250 pg/ml Aβ42, respectively. We concluded from our data that microglial function was not adversely affected until Flot1 shifted out of fractions 1 and 2. With continued celecoxib treatment, Flot1 re-appeared in both raft and heavier, non-raft fractions. This could be due to the changing properties of the raft fractions, as they assume dynamics more similar to the non-raft fractions with prolonged celecoxib treatment. Of note is the significant decrease in Flot1 protein level following treatment with celecoxib, filipin or Aβ42. Since Flot1 is an integral part of rafts and has recently been shown to be involved in a number of signaling cascades (Babuke and Tikkanen 2007), disrupting rafts could have adverse effects on phagocytic signaling and the associated proteins. Therefore, Flot1 protein levels would decline following raft disruption, as observed following treatment with filipin or 250 pg/ml Aβ42 (Fig 2 & Fig 3).

Inhibition of COX-2 and prostaglandin-E2 synthesis should stimulate phagocytosis (Aronoff et al. 2004). It may, therefore, seem counter-intuitive that celecoxib treatment initially stimulated phagocytosis but later inhibited it, whereas direct Aβ42 treatments, known to increase COX-2 expression (Hull et al. 2006), led to inhibition at all time points (Fig. 3). This suggests that some other property of the drug is affecting microglial phagocytosis. It could be that the production of monomeric Aβ42 by celecoxib (Kukar et al. 2005), which does not inhibit uptake, is responsible for the initial phagocytic spike at 3 hrs, where celecoxib induced Aβ42 levels of approximately 400 pg/ml. Continued accumulation at 37°C, however, facilitates fibrillization and, in this form, Aβ42 is difficult to phagocytize (Sadowski et al. 2006). This may explain our observations at 24–27 hrs of treatment. Also, in figure 1 we demonstrated that exogenously added fibrillar Aβ42 inhibits phagocytosis at concentrations above 250 pg/ml. This amount of Aβ42 is in addition to that which is normally produced by the cell. This is supported by the fact that continued accumulation of secreted Aβ42 in the media inhibited phagocytosis (Fig 4 & Fig 5). Similar properties are exhibited by monomeric and aggregated α-synuclein (Park et al. 2008).

Since one of our questions was whether high Aβ42 concentrations over an extended period of time would interfere with microglial phagocytosis, we did not examine acute effects of direct Aβ42 treatment over the short term. Furthermore, celecoxib did not significantly increase Aβ42 levels before 3 hrs. In our hands, we found that prolonged celecoxib treatment inhibited phagocytosis, despite the fact that some COX inhibitors can suppress phagocytic inhibition (Koenigsknecht-Talboo and Landreth 2005). Possible reasons for this contradiction may be that those investigators used immortalized BV-2 cells whereas we used primary microglia cells, the former tend to have a higher baseline activation state than primary microglia. Additionally, the aforementioned study used ibuprofen, which unlike celecoxib, does not cause increased Aβ42(Gasparini et al. 2004). Although contributing to an increased microglial activation state, these factors combined, could send the cell into senescence, thereby decreasing the overall phagocytic capability (Streit 2006; Streit et al. 2005). Despite evidence to support a potential therapeutic use for some NSAIDs, conclusive effects are still disputable; the effectiveness being related to many factors including type of drug, concentration reaching the brain and varied vulnerabilities of different neuronal populations (Leuchtenberger et al. 2006).

Inflammatory environments affect phagocytosis

Microglial clearance of Aβ42 appears to be regulated by the inflammatory environment (Koenigsknecht-Talboo and Landreth 2005). Further, aggregated and fibrillar Aβ42 activate microglia which can initiate signaling cascades via a number of chemokines and cytokines (Griffin 2006). There is ample evidence demonstrating that Aβ42 stimulates phagocytosis and activates microglia (Butovsky et al. 2005; Chung et al. 1999; Koenigsknecht-Talboo and Landreth 2005; Koenigsknecht and Landreth 2004). Our results using isolated microglia were consistent with these observations and demonstrated that increased Aβ42 exposure, resulting from direct application or pharmacological induction, resulted in morphological activation, the elevation of mRNA levels of pro-inflammatory cytokines IL-1α and IL-6, and decreased mRNA levels for both TGF-β1 and IGF-1 (Fig. 7). Since IL-6 can have anti-inflammatory effects (Quintana et al. 2008), it is possible that its upregulation may be an attempt at protection against Aβ42-induced toxicity. The decrease in levels of TGF-β1 may be related to the effect of COX-2 inhibition (Liu et al. 2007). The oscillations seen for IGF-1 and TGF-β1 may, therefore, be the combined result of anti-inflammatory aspect of celecoxib and the pro-inflammatory effect of Aβ42. Increased IL-1α and IL-6, coupled to decreased TGF-β1 and IGF1, could impact cellular functions including processing of APP (Griffin 2006), early lymphocyte recruitment, astrocyte signaling (Stipursky and Gomes 2007), cell migration (Coras et al. 2007), synaptic plasticity and phagocytosis (Koenigsknecht-Talboo and Landreth 2005).

Receptor recruitment to rafts during phagocytosis

Specific recruitment of proteins to rafts is important for the regulation of different signaling cascades (Kim et al. 2006). Therefore, there is a strong possibility that raft recruitment of protein receptors is also involved in phagocytic regulation. This is supported by observations that receptor recognition occurs at the membrane surface and that receptors involved in phagocytosis, such as CD36, are present in rafts (Thorne et al. 2000). The specificity of different receptors participating in phagocytosis depends on both cell type and the material being cleared (Gregory and Devitt 2004; Koizumi et al. 2007; Lucas et al. 2006; Makranz et al. 2006; Ren et al. 1995; Seitz et al. 2007). Specifically, Aβ42 clearance is facilitated by a number of different receptors including the TLRs, CD14, Fc, complement, integrin-associated proteins like CD47, and scavenger receptors such as CD36 (Bamberger et al. 2003; Koenigsknecht and Landreth 2004; Liu et al. 2005; Tahara et al. 2006). Based on their involvement in various types of phagocytosis, we investigated whether CD36 and CD47 were actively recruited to rafts during phagocytosis. In this process, we hypothesized that structurally intact rafts are required for the juxtaposition of different receptor combinations involved in phagocytosis. We concluded that specific recruitment of CD36, but not CD47, to rafts was necessary for phagocytosis of Aβ42, supporting a pivotal role for rafts in this process.

Displacement of CD36 from rafts may interfere with the tethering or signaling phase of phagocytosis (Gregory and Devitt 2004). Redistribution of CD36 in microglia under raft-impairing, high Aβ42 conditions demonstrates that its presence in rafts is dependent upon maintenance of raft structural integrity. Engagement of CD36 in phagocytosis suppresses pro-inflammatory cytokine signaling (Bottcher et al. 2006). Thus, the observed destabilization of CD36-containing rafts in microglia could repress phagocytosis and increase the expression of the observed pro-inflammatory cytokines. This work supports studies from the Moore lab, where CD36 was one of the primary receptors affected by Aβ42, creating a pro-inflammatory environment through the inability of microglia to clear oxidized phospolipid-containing ligands (Kunjathoor et al. 2004).

Regarding CD47 involvement in microglia phagocytosis, it is likely that its actions are primarily those of a negative regulator. This supports previous work characterizing “don’t eat me signals” on apoptotic red blood cells (Oldenborg et al. 2000). That CD47 re-enters rafts slowly during phagocytic inhibition further indicates a regulatory role for rafts and suggests a selective compromise in the integrity of a defined subset of rafts, e.g. CD36-containing rafts, while others remain intact. Importantly, this data further suggests that CD36 and CD47 are not present within the same raft compartment.

Raft populations consist of ‘reserve rafts’, as well as, ‘stabilized receptor-clustered rafts’ (Kusumi et al. 2004). This implies that the different raft populations may be activated independently. Our identification of two distinct groups of raft clusters during phagocytosis supports this. Thus, under phagocytic conditions, only specific raft populations, i.e. CD36-containing rafts, are mobilized to the phagocytic cup. The subset of rafts outside of the cup may be part of the reserve population, or may be platforms for signaling processes other than phagocytoic cup formation. In this study, we demonstrated that raft disruption, either by cholesterol sequestration or high Aβ42 conditions, interfered with raft aggregation and phagocytic cup formation. Disruption of raft integrity may affect raft homeostasis, resulting in aberrant aggregation and altered downstream signaling. This attests to the highly dynamic, yet fragile nature of rafts.

Recent work suggests that discrete membrane organizations may represent a basic cellular design required for signal transduction (Tian et al. 2007). Precedence for this comes from studies which report that alteration of raft integrity can lead to trafficking defects, as seen in Niemann-Pick (Simons and Gruenberg 2000) and Batten diseases (Persaud-Sawin et al. 2004). Additionally, prion diseases such as Creutzfeld-Jacob disease (CJD) and bovine spongiform encephalopathy require rafts for protein processing (Fantini et al. 2002), and the over-expression of α-synuclein in Parkinson’s Disease can upregulate the raft-related caveolar protein, caveolin 1 (Hashimoto et al. 2003) and activate microglia (Zhang et al. 2005).


The data presented here demonstrates that in an environment where there is a constant, but low level of Aβ42, microglia might be more responsive to phagocytic stimulation. Speculatively, this may be one reason why treatment of neurodegenerative diseases with NSAIDs has not been successful. Our observations suggest that current dosing regimes with selective NSAIDs may increase γ-secretase activity over time, leading to Aβ42 build-up, downstream IL-1 and IL-6 increases and decreased microglial phagocytic capacity. The anti-inflammatory component provided by COX-2 inhibition may be over-ridden by the production of Aβ42, such that the subsequent inflammatory environment probably prevents microglia from adapting successfully. The data presented here provides novel insight into the importance of rafts in the microglial phagocytic machinery. We provide the first report that membrane raft aggregation in the phagocytic cup area is a prerequisite for efficient microglial phagocytosis. Deficiencies in microglial function as well as raft disruption appear to be central themes in many degenerative diseases including AD, Parkinson’s Disease and prion disease (Ciesielski-Treska et al. 2004; Fiala et al. 2005; Salman et al. 1999). Therefore, rafts may be a necessary factor that, when disrupted, significantly contribute to the overall degenerative process. Understanding these mechanisms can allow certain raft components e.g., CD36 or Flot1, to be manipulated or used as targets for therapeutic intervention in the treatment of neurodegeneration.

Supplementary Material


The authors would like to thank Drs. Michael Fessler and Rose-Mary Boustany for their assistance in reviewing the manuscript. This research has been supported by the Division of Intramural Research of NIEHS within NIH under project #1Z01ES101623-05 and the NIEHS chemistry contract to Research Triangle Institute #10015-42-05.


Alzheimer’s Disease
Apolipoprotein E
Amyoid precursor protein
amyloid Aβ42
Creutzfeld-Jacob disease
detergent-resistane membrane
FcRγI or FcRγIII
constant fragment of receptor γ subtype I or III
insulin-like growth factor 1
non-steroidal anti-inflammatory drug
transforming growth factor-β
Parkinson’s Disease
pathogen-associated molecular patterns
pattern recognition receptors
postnatal day 2
scavenger receptor family A/B
transferrin receptor
Toll-like receptors


  • Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21(3):383–421. [PubMed]
  • Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol. 2004;173(1):559–565. [PubMed]
  • Arvanitis DN, Min W, Gong Y, Heng YM, Boggs JM. Two types of detergent-insoluble, glycosphingolipid/cholesterol-rich membrane domains from isolated myelin. J Neurochem. 2005;94(6):1696–1710. [PubMed]
  • Babuke T, Tikkanen R. Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol. 2007;86(9):525–532. [PubMed]
  • Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23(7):2665–2674. [PubMed]
  • Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916–919. [PubMed]
  • Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kalden JR, Voll RE. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Arthritis Rheum. 2006;54(3):927–938. [PubMed]
  • Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem. 2000;275(23):17221–17224. [PubMed]
  • Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell. 1992;68(3):533–544. [PubMed]
  • Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci. 2005;29(3):381–393. [PubMed]
  • Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. Brain Res Rev. 2007;53(2):344–354. [PubMed]
  • Cheng J, Ohsaki Y, Tauchi-Sato K, Fujita A, Fujimoto T. Cholesterol depletion induces autophagy. Biochem Biophys Res Commun. 2006;351(1):246–252. [PubMed]
  • Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem. 1999;274(45):32301–32308. [PubMed]
  • Ciesielski-Treska J, Grant NJ, Ulrich G, Corrotte M, Bailly Y, Haeberle AM, Chasserot-Golaz S, Bader MF. Fibrillar prion peptide (106–126) and scrapie prion protein hamper phagocytosis in microglia. Glia. 2004;46(2):101–115. [PubMed]
  • Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002;160(1):101–112. [PubMed]
  • Coras R, Holsken A, Seufert S, Hauke J, Eyupoglu IY, Reichel M, Trankle C, Siebzehnrubl FA, Buslei R, Blumcke I, et al. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther. 2007;6(6):1745–1754. [PubMed]
  • Cuzzocrea S, Mazzon E, Sautebin L, Dugo L, Serraino I, De Sarro A, Caputi AP. Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem Pharmacol. 2002;63(4):785–795. [PubMed]
  • Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160(1):113–123. [PMC free article] [PubMed]
  • El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197(12):1657–1666. [PMC free article] [PubMed]
  • Eto M, Yoshikawa H, Fujimura H, Naba I, Sumi-Akamaru H, Takayasu S, Itabe H, Sakoda S. The role of CD36 in peripheral nerve remyelination after crush injury. Eur J Neurosci. 2003;17(12):2659–2666. [PubMed]
  • Fantini J, Garmy N, Mahfoud R, Yahi N. Lipid rafts: structure, function and role in HIV, Alzheimers and prion diseases. Expert Rev Mol Med. 2002;2002:1–22. [PubMed]
  • Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2005;7(3):221–232. discussion 255-62. [PubMed]
  • Fullekrug J, Simons K. Lipid rafts and apical membrane traffic. Ann N Y Acad Sci. 2004;1014:164–169. [PubMed]
  • Gamerdinger M, Clement AB, Behl C. Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. Mol Pharmacol. 2007;72(1):141–151. [PubMed]
  • Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem. 2004;91(3):521–536. [PubMed]
  • Gregory CD, Devitt A. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology. 2004;113(1):1–14. [PubMed]
  • Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr. 2006;83(2):470S–474S. [PubMed]
  • Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006;3:5. [PMC free article] [PubMed]
  • Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol. 2006;7(6):456–462. [PMC free article] [PubMed]
  • Hashimoto M, Takenouchi T, Rockenstein E, Masliah E. Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem. 2003;85(6):1468–1479. [PubMed]
  • Hull M, Muksch B, Akundi RS, Waschbisch A, Hoozemans JJ, Veerhuis R, Fiebich BL. Amyloid beta peptide (25–35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. Neurochem Int. 2006;48(8):663–672. [PubMed]
  • Janich P, Corbeil D. GM1 and GM3 gangliosides highlight distinct lipid microdomains within the apical domain of epithelial cells. FEBS Lett. 2007;581(9):1783–1787. [PubMed]
  • Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J. 2002;366(Pt 3):831–837. [PubMed]
  • Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006;117(5):979–987. quiz 988. [PubMed]
  • Kay JG, Murray RZ, Pagan JK, Stow JL. Cytokine secretion via cholesterol-rich lipid raft-associated SNAREs at the phagocytic cup. J Biol Chem. 2006;281(17):11949–11954. [PubMed]
  • Keystone EC, Schorlemmer HU, Pope C, Allison AC. Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum. 1977;20(7):1396–1401. [PubMed]
  • Kim HY, Park SJ, Joe EH, Jou I. Raft-mediated Src homology 2 domain-containing proteintyrosine phosphatase 2 (SHP-2) regulation in microglia. J Biol Chem. 2006;281(17):11872–11878. [PubMed]
  • Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25(36):8240–8249. [PubMed]
  • Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004;24(44):9838–9846. [PubMed]
  • Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007;446(7139):1091–1095. [PMC free article] [PubMed]
  • Korotzer AR, Pike CJ, Cotman CW. beta-Amyloid peptides induce degeneration of cultured rat microglia. Brain Res. 1993;624(1–2):121–125. [PubMed]
  • Koshinaga M, Katayama Y, Fukushima M, Oshima H, Suma T, Takahata T. Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J Neurotrauma. 2000;17(3):185–192. [PubMed]
  • Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis. 2006;11(10):1709–1726. [PubMed]
  • Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11(5):545–550. [PubMed]
  • Kunjathoor VV, Tseng AA, Medeiros LA, Khan T, Moore KJ. beta-Amyloid promotes accumulation of lipid peroxides by inhibiting CD36-mediated clearance of oxidized lipoproteins. J Neuroinflammation. 2004;1(1):23. [PMC free article] [PubMed]
  • Kusumi A, Koyama-Honda I, Suzuki K. Molecular dynamics and interactions for creation of stimulation-induced stabilized rafts from small unstable steady-state rafts. Traffic. 2004;5(4):213–230. [PubMed]
  • Langhorst MF, Reuter A, Stuermer CA. Scaffolding microdomains and beyond: the function of reggie/flotillin proteins. Cell Mol Life Sci. 2005;62(19–20):2228–2240. [PubMed]
  • Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Curr Pharm Des. 2006;12(33):4337–4355. [PubMed]
  • Lingwood D, Simons K. Detergent resistance as a tool in membrane research. Nat Protoc. 2007;2(9):2159–2165. [PubMed]
  • Liu H, Peng Y, Liu F, Li J, Chen X, Liu Y, Zhang H. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int. 2007;31(5):508–515. [PubMed]
  • Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain. 2005;128(Pt 8):1778–1789. [PubMed]
  • Lucas M, Stuart LM, Zhang A, Hodivala-Dilke K, Febbraio M, Silverstein R, Savill J, Lacy-Hulbert A. Requirements for apoptotic cell contact in regulation of macrophage responses. J Immunol. 2006;177(6):4047–4054. [PubMed]
  • Macdonald JL, Pike LJ. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res. 2005;46(5):1061–1067. [PubMed]
  • Makranz C, Cohen G, Reichert F, Kodama T, Rotshenker S. cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages. Glia. 2006;53(4):441–448. [PubMed]
  • McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85(3):890–902. [PMC free article] [PubMed]
  • Mitrasinovic OM, Murphy GM., Jr Accelerated phagocytosis of amyloid-beta by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor. J Biol Chem. 2002;277(33):29889–29896. [PubMed]
  • Monaco S, Zanusso G, Mazzucco S, Rizzuto N. Cerebral amyloidoses: molecular pathways and therapeutic challenges. Curr Med Chem. 2006;13(16):1903–1913. [PubMed]
  • Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem. 2002;277(49):47373–47379. [PubMed]
  • Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120(Pt 23):4081–4091. [PubMed]
  • O'Banion MK, Chang JW, Kaplan MD, Yermakova A, Coleman PD. Glial and neuronal expression of cyclooxygenase-2: relevance to Alzheimer's disease. Adv Exp Med Biol. 1997;433:177–180. [PubMed]
  • O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes. 2002;51(8):2481–2488. [PubMed]
  • Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051–2054. [PubMed]
  • Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17(3):553–565. [PubMed]
  • Park JY, Paik SR, Jou I, Park SM. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: Implications for Parkinson's disease. Glia. 2008 [PubMed]
  • Persaud-Sawin DA, McNamara JO, 2nd, Rylova S, Vandongen A, Boustany RM. A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr Res. 2004;56(3):449–463. [PubMed]
  • Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J. 2004;378(Pt 2):281–292. [PubMed]
  • Puglielli L. Aging of the brain, neurotrophin signaling, and Alzheimer's disease: Is IGF1-R the common culprit? Neurobiol Aging. 2007 [PMC free article] [PubMed]
  • Quintana A, Molinero A, Borup R, Nielsen FC, Campbell IL, Penkowa M, Hidalgo J. Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome. Dev Neurobiol. 2008;68(2):195–208. [PubMed]
  • Reddy SM, Hsiao KH, Abernethy VE, Fan H, Longacre A, Lieberthal W, Rauch J, Koh JS, Levine JS. Phagocytosis of apoptotic cells by macrophages induces novel signaling events leading to cytokine-independent survival and inhibition of proliferation: activation of Akt and inhibition of extracellular signal-regulated kinases 1 and 2. J Immunol. 2002;169(2):702–713. [PubMed]
  • Ren Y, Silverstein RL, Allen J, Savill J. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med. 1995;181(5):1857–1862. [PMC free article] [PubMed]
  • Ricciarelli R, D'Abramo C, Zingg JM, Giliberto L, Markesbery W, Azzi A, Marinari UM, Pronzato MA, Tabaton M. CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer's disease. Free Radic Biol Med. 2004;36(8):1018–1024. [PubMed]
  • Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 2002;40(2):260–269. [PubMed]
  • Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103(49):18787–18792. [PubMed]
  • Salman H, Bergman M, Bessler H, Fenig E, Weiss J, Beilin B, Djaldetti M. Decreased phagocytic capacity of rat peritoneal macrophages following photon abdominal irradiation. Cancer Lett. 1999;147(1–2):175–179. [PubMed]
  • Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. J Immunol. 2007;178(9):5635–5642. [PubMed]
  • Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001;3(1):75–80. [PubMed]
  • Seveau S, Eddy RJ, Maxfield FR, Pierini LM. Cytoskeleton-dependent membrane domain segregation during neutrophil polarization. Mol Biol Cell. 2001;12(11):3550–3562. [PMC free article] [PubMed]
  • Sharma P, Varma R, Sarasij RC, Ira, Gousset K, Krishnamoorthy G, Rao M, Mayor S. Nanoscale organization of multiple GPI-anchored proteins in living cell membranes. Cell. 2004;116(4):577–589. [PubMed]
  • Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia. 2007;55(4):412–424. [PubMed]
  • Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110(5):597–603. [PMC free article] [PubMed]
  • Simons K, Gruenberg J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol. 2000;10(11):459–462. [PubMed]
  • Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387(6633):569–572. [PubMed]
  • Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95(11):6460–6464. [PubMed]
  • Stipursky J, Gomes FC. TGF-beta1/SMAD signaling induces astrocyte fate commitment in vitro: implications for radial glia development. Glia. 2007;55(10):1023–1033. [PubMed]
  • Streit WJ. Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci. 2006;29(9):506–510. [PubMed]
  • Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL. Role of microglia in the central nervous system's immune response. Neurol Res. 2005;27(7):685–691. [PubMed]
  • Stuart LM, Bell SA, Stewart CR, Silver JM, Richard J, Goss JL, Tseng AA, Zhang A, El Khoury JB, Moore KJ. CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex. J Biol Chem. 2007;282(37):27392–27401. [PubMed]
  • Swanson JA, Johnson MT, Beningo K, Post P, Mooseker M, Araki N. A contractile activity that closes phagosomes in macrophages. J Cell Sci. 1999;112(Pt 3):307–316. [PubMed]
  • Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 2006;129(Pt 11):3006–3019. [PMC free article] [PubMed]
  • Thorne RF, Law EG, Elith CA, Ralston KJ, Bates RC, Burns GF. The association between CD36 and Lyn protein tyrosine kinase is mediated by lipid. Biochem Biophys Res Commun. 2006;351(1):51–56. [PubMed]
  • Thorne RF, Marshall JF, Shafren DR, Gibson PG, Hart IR, Burns GF. The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J Biol Chem. 2000;275(45):35264–35275. [PubMed]
  • Tian T, Harding A, Inder K, Plowman S, Parton RG, Hancock JF. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nat Cell Biol. 2007;9(8):905–914. [PubMed]
  • Tohyama Y, Yamamura H. Complement-mediated phagocytosis--the role of Syk. IUBMB Life. 2006;58(5–6):304–308. [PubMed]
  • Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006;281(41):31002–31011. [PubMed]
  • Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita T, Iwatsubo T, Hamakubo T, Kodama T. Association of active gamma-secretase complex with lipid rafts. J Lipid Res. 2005;46(5):904–912. [PubMed]
  • Wang R, Town T, Gokarn V, Flavell RA, Chandawarkar RY. HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and PI3K pathways. J Surg Res. 2006a;136(1):58–69. [PubMed]
  • Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today. 2006b;11(19–20):931–938. [PubMed]
  • Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7(5):612–618. [PubMed]
  • Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. Faseb J. 2005;19(6):533–542. [PubMed]